← Back to headlines
Biotech Stocks Gain After FDA Reverses Stance on UniQure
Regenxbio and Replimune were among the top gainers in the biotech sector following a U-turn by the FDA regarding UniQure, indicating a positive market response to the regulatory development.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
